ArticleOphthalmology science2026
Choroidal Vascular Remodeling and Retinal Response After Aflibercept Loading in Diabetic Macular Edema.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Choriocapillaris Flow and Retinal Vascular Fractal Dimension in Dry Age-Related Macular Degeneration.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate choroidal changes after aflibercept treatment for diabetic macular edema (DME) and to assess their association with treatment response. Design: A retrospective interventional cohort study. Subjects: Thirty eyes from 30 patients who were injection-naïve for DME and received initial 5 monthly loading injections of aflibercept. Methods: Choroidal and retinal changes after loading injections were analyzed using spectral-domain OCT with enhanced depth imaging (EDI-SD-OCT) and ultra-widefield indocyanine green angiography (UWF-ICGA). The correlation between choroidal and retinal changes, along with factors associated with a good treatment response, was investigated. Main Outcome Measures: Changes in subfoveal choroidal thickness (sfCT), total choroidal area (TA), luminal area (LA), stromal area (SA), and choroidal vascularity index (CVI) measured by EDI-SD-OCT; choroidal vascular density (CVD) and choroidal fractal dimension (CFD) of macula and widefield assessed by UWF-ICGA; as well as treatment response, including central retinal thickness (CRT) and inflammatory hyperreflective foci (HRF) evaluated through EDI-SD-OCT. Results: Aflibercept induced a significant reduction in sfCT, TA, LA, and SA (all Conclusions: Aflibercept treatment induces stromal-dominant choroidal thinning with a consequent increase in CVI. This choroidal remodeling may be associated with the anatomical resolution of DME through mechanisms involving reduction of inflammatory HRF. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.